Search Results - "P. Casali"

Data protection and research in the European Union: a major step forward, with a step back by Casali, P.G., Vyas, M.

Get full text

Rare cancers: from centralized referral to networking by Casali, P.G.

Get full text

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Casali, P. G., Blay, J.-Y.

Get full text

Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas by Gronchi, A., Miceli, R., Colombo, C., Stacchiotti, S., Collini, P., Mariani, L., Sangalli, C., Radaelli, S., Sanfilippo, R., Fiore, M., Casali, P.G.

“…The purpose of the study was to retrospectively reassess in our institutional series at a longer follow-up the value of a systematic attempt to carry out wide…”
Get full text

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study by Grignani, G., Palmerini, E., Dileo, P., Asaftei, S.D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P.G., Ferrari, S., Aglietta, M.

“…After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades. Recently,…”
Get full text

Risks of the new EU Data protection regulation: an ESMO position paper endorsed by the European oncology community by Casali, P.G.

Get full text

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Casali, P. G., Blay, J.-Y.

Get full text

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect by Stacchiotti, S., Negri, T., Zaffaroni, N., Palassini, E., Morosi, C., Brich, S., Conca, E., Bozzi, F., Cassinelli, G., Gronchi, A., Casali, P.G., Pilotti, S.

“…The purpose of this study was to confirm sunitinib activity in alveolar soft part sarcoma (ASPS) and to report on new insights into the molecular bases…”
Get full text

Phase II study on lapatinib in advanced EGFR-positive chordoma by Stacchiotti, S., Tamborini, E., Lo Vullo, S., Bozzi, F., Messina, A., Morosi, C., Casale, A., Crippa, F., Conca, E., Negri, T., Palassini, E., Marrari, A., Palmerini, E., Mariani, L., Gronchi, A., Pilotti, S., Casali, P.G.

“…To report on a prospective, investigator-driven, phase II study on lapatinib in epidermal growth factor receptor (EGFR)-positive advanced chordoma patients…”
Get full text

Sunitinib malate in solitary fibrous tumor (SFT) by Stacchiotti, S., Negri, T., Libertini, M., Palassini, E., Marrari, A., De Troia, B., Gronchi, A., Dei Tos, A.P., Morosi, C., Messina, A., Pilotti, S., Casali, P.G.

“…To report on sunitinib activity in a retrospective series of 35 solitary fibrous tumor (SFT) treated at a single institution. From April 2008, 35 patients with…”
Get full text

Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group by Gronchi, A., Colombo, C., Le Péchoux, C., Dei Tos, A.P., Le Cesne, A., Marrari, A., Penel, N., Grignani, G., Blay, J.Y., Casali, P.G., Stoeckle, E., Gherlinzoni, F., Meeus, P., Mussi, C., Gouin, F., Duffaud, F., Fiore, M., Bonvalot, S.

“…Desmoid-type fibromatosis (DF) is a rare locally aggressive monoclonal proliferation of myofibroblasts lacking metastatic capacity. It may be observed in…”
Get full text

Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas by Casali, P G

“…Medical treatment of adult soft tissue sarcomas is more and more dictated by the histological subtype, in a family of rare cancers made up of dozens of these…”
Get full text

‘Rare cancers’: not all together in clinical studies by Casali, P.G., Licitra, L., Frezza, A.M., Trama, A.

Get full text

The Effect of Crackers Enriched with Camelina Sativa Oil on Omega-3 Serum Fatty Acid Composition in Older Adults: A Randomized Placebo-Controlled Pilot Trial by De Giuseppe, R., Di Napoli, I., Tomasinelli, C. E., Vincenti, Alessandra, Biino, G., Sommella, E., Ferron, L., Campiglia, P., Ferrara, F., Casali, P. M., Cena, H.

“…Background Camelina sativa oil is one of the richest dietary sources of omega-3, with polyunsaturated fatty acids amounts of over 50%, linolenic acid content…”
Get full text

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group by Stacchiotti, S., Gronchi, A., Fossati, P., Akiyama, T., Alapetite, C., Baumann, M., Blay, J.Y., Bolle, S., Boriani, S., Bruzzi, P., Capanna, R., Caraceni, A., Casadei, R., Colia, V., Debus, J., Delaney, T., Desai, A., Dileo, P., Dijkstra, S., Doglietto, F., Flanagan, A., Froelich, S., Gardner, P.A., Gelderblom, H., Gokaslan, Z.L., Haas, R., Heery, C., Hindi, N., Hohenberger, P., Hornicek, F., Imai, R., Jeys, L., Jones, R.L., Kasper, B., Kawai, A., Krengli, M., Leithner, A., Logowska, I., Martin Broto, J., Mazzatenta, D., Morosi, C., Nicolai, P., Norum, O.J., Patel, S., Penel, N., Picci, P., Pilotti, S., Radaelli, S., Ricchini, F., Rutkowski, P., Scheipl, S., Sen, C., Tamborini, E., Thornton, K.A., Timmermann, B., Torri, V., Tunn, P.U., Uhl, M., Yamada, Y., Weber, D.C., Vanel, D., Varga, P.P., Vleggeert-Lankamp, C.L.A., Casali, P.G., Sommer, J.

“…Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among experts regarding appropriate…”
Get full text

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure by George, S, Blay, J.Y, Casali, P.G, Le Cesne, A, Stephenson, P, DePrimo, S.E, Harmon, C.S, Law, C.N.J, Morgan, J.A, Ray-Coquard, I, Tassell, V, Cohen, D.P, Demetri, G.D

“…Abstract Aims To assess the antitumour activity, safety, pharmacokinetics and pharmacodynamics of continuous daily sunitinib dosing in patients with…”
Get full text

Response to imatinib plus sirolimus in advanced chordoma by Stacchiotti, S., Marrari, A., Tamborini, E., Palassini, E., Virdis, E., Messina, A., Crippa, F., Morosi, C., Gronchi, A., Pilotti, S., Casali, P. G.

“…Background: Imatinib (IM) is active in advanced chordoma. The evidence of upstream and/or downstream mammalian target of rapamycin (mTOR) pathway activation…”
Get full text

Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network by Stacchiotti, S., Palassini, E., Sanfilippo, R., Vincenzi, B., Arena, M.G., Bochicchio, A.M., De Rosa, P., Nuzzo, A., Turano, S., Morosi, C., Dei Tos, A.P., Pilotti, S., Casali, P.G.

“…Angiosarcoma is a highly aggressive soft tissue sarcoma. Responses to anthracyclines plus/minus ifosfamide, and taxanes alone or in combination with…”
Get full text

Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? by Mussi, C., Ronellenfitsch, U., Jakob, J., Tamborini, E., Reichardt, P., Casali, P.G., Fiore, M., Hohenberger, P., Gronchi, A.

“…Surgical indication for metastatic gastrointestinal stromal tumor (GIST) treated with imatinib is not yet established. We analyzed 80 patients who underwent…”
Get full text

Mode of action of trabectedin in myxoid liposarcomas by Di Giandomenico, S, Frapolli, R, Bello, E, Uboldi, S, Licandro, S A, Marchini, S, Beltrame, L, Brich, S, Mauro, V, Tamborini, E, Pilotti, S, Casali, P G, Grosso, F, Sanfilippo, R, Gronchi, A, Mantovani, R, Gatta, R, Galmarini, C M, Sousa-Faro, J M F, D'Incalci, M

“…To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific…”
Get full text